Your browser doesn't support javascript.
loading
CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation.
Wang, Dan-Dan; Chen, Ying; Chen, Zi-Bo; Yan, Fang-Jie; Dai, Xiao-Yang; Ying, Mei-Dan; Cao, Ji; Ma, Jian; Luo, Pei-Hua; Han, Yong-Xin; Peng, Yong; Sun, Ying-Hui; Zhang, Hui; He, Qiao-Jun; Yang, Bo; Zhu, Hong.
Afiliación
  • Wang DD; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Chen Y; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Chen ZB; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Yan FJ; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Dai XY; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Ying MD; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Cao J; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Ma J; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Luo PH; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Han YX; Department of Medicinal Chemistry, Centaurus BioPharma Co., Ltd, Beijing, China.
  • Peng Y; Department of Discovery Biology, Centaurus BioPharma Co., Ltd, Beijing, China.
  • Sun YH; Department of Discovery Biology, Centaurus BioPharma Co., Ltd, Beijing, China.
  • Zhang H; Department of Discovery Biology, Centaurus BioPharma Co., Ltd, Beijing, China.
  • He QJ; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Yang B; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Zhu H; Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China. hongzhu@zju.edu.cn.
Mol Cancer Ther ; 15(12): 2916-2925, 2016 12.
Article en En | MEDLINE | ID: mdl-27638856
Asunto(s)
Buscar en Google
Imprimir
XML
PubMed Links

Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Piridinas / Carcinoma Hepatocelular / Inhibidores de Proteínas Quinasas / Quinasa 1 de Adhesión Focal / Anilidas / Neoplasias Hepáticas Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2016 Tipo del documento: Article País de afiliación: China
Buscar en Google
Imprimir
XML
PubMed Links

Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Piridinas / Carcinoma Hepatocelular / Inhibidores de Proteínas Quinasas / Quinasa 1 de Adhesión Focal / Anilidas / Neoplasias Hepáticas Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2016 Tipo del documento: Article País de afiliación: China